Changchun BCHT Biotechnology Co.
Dedicated to biotechnology, creating a healthy future.
Changchun BCHT Biotechnology Co. (hereinafter referred to as the “Company” or “BCG Biotech”) was founded in 2004 and has been dedicated to the biopharmaceutical sector for the past 20 years. It is a high-tech biopharmaceutical enterprise primarily engaged in the research and development, production, and sales of human vaccines. The company’s core products focus on three major categories: live attenuated varicella vaccine, lyophilized intranasal live attenuated influenza vaccine, and live attenuated herpes zoster vaccine. The company was listed on the Shanghai Stock Exchange in June 2021.
The company has established three centers: the National-level Enterprise Technology Center, the Jilin Province Modern Vaccine Engineering Research Center, and the Jilin Province BCG Vaccine Science and Technology Innovation Center; two laboratories: the National Engineering Laboratory for AIDS Vaccines, and a joint laboratory (BCG Bio + Institute of Pathogen Biology, Chinese Academy of Medical Sciences); and one national postdoctoral research workstation. The company is recognized as a National High-tech Enterprise, a key enterprise under special monitoring and coordination by the Ministry of Industry and Information Technology for economic operations, a Single Champion Enterprise in Manufacturing in Jilin Province, and the leading unit of the Jilin Province Biopharmaceutical Industry Science and Technology Innovation Alliance. It has received honors including the China Patent Excellence Award, the Third Prize of the Jilin Province Science and Technology Progress Award, and the Changbai Mountain Pharmaceutical Innovation Award (for Achievement Transformation) of Jilin Province.
Company establishment date
Total land area
Existing employees
Medicines benefit countries and regions.
The company’s flagship products include the live attenuated varicella vaccine, the lyophilized intranasal live attenuated influenza vaccine, and the live attenuated herpes zoster vaccine. The company focuses on the research, development, manufacturing, and sales of human vaccines in the biopharmaceutical sector. Its live attenuated varicella vaccine is the first domestically produced varicella vaccine that has eliminated animal-derived gelatin and boasts a shelf life of up to 36 months—exhibiting the best stability among similar products and maintaining a leading market share nationwide for many years. The lyophilized intranasal live attenuated influenza vaccine has been included in the World Health Organization (WHO) Global Influenza Vaccine Action Plan (GAP) initiative; it is the only domestically produced live attenuated influenza vaccine administered via intranasal spray. The live attenuated herpes zoster vaccine is the first domestically developed vaccine designed specifically for the prevention of herpes zoster, achieving domestic substitution in the herpes zoster vaccine market. Currently, the company’s products are available in 31 provinces, autonomous regions, and municipalities across mainland China—excluding Hong Kong, Macao, and Taiwan—and are also exported to countries such as India and Pakistan.
The company takes “market-driven, technology-led, and policy-supported” approaches as its innovation engines, seamlessly integrating market demands, technological development trends, and the company’s operational and developmental plans. Numerous research institutions—including Jilin University, the Institute of Pathogen Biology of the Chinese Academy of Medical Sciences, the Institute of Military Veterinary Medicine of the Academy of Military Medical Sciences, Jilin Agricultural University, Changchun University of Technology, and Jilin College of Pharmaceutical Sciences—have established collaborative partnerships among industry, academia, and research. Advanced technologies are deeply integrated with industrialization platforms, providing strong impetus for the development of the regional biopharmaceutical industry chain.